Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rapid test could slash TB diagnosis time in High-Burden regions

NCT ID NCT04752592

Diagnosis Sponsor: Norwegian Institute of Public Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new rapid blood test called SeroSelectTB to see if it can diagnose active tuberculosis (TB) faster than current methods. Over 9,000 adults in South Africa, Tanzania, and Ethiopia who were unwell and suspected of having TB or pneumonia took part. The goal is to provide same-day results at local clinics, reducing delays in starting treatment and potentially lowering the spread of TB.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9,097 people

The number who actually took part.

Started

Sep 2021

Finished

Dec 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Informed Consent Form signed * Unwell, suspected to have TB or pneumonia Exclusion Criteria: * Currently receiving TB treatment * On TB treatment past 30 days or more, or last dose less than 1 month before enrolment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

active tuberculosis pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis, pulmonary

Contacts and locations

Locations

  • Kilimanjaro region, Tanzania

    Moshi, Tanzania

  • Sidama region

    Awasa, Ethiopia

  • Stellenbosch University Clinics

    Cape Town, Western Cape, 7505, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.